Cytokinetics Stock Fundamentals
| CYTK Stock | USD 67.00 0.93 1.37% |
Cytokinetics fundamentals help investors to digest information that contributes to Cytokinetics' financial success or failures. It also enables traders to predict the movement of Cytokinetics Stock. The fundamental analysis module provides a way to measure Cytokinetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytokinetics stock.
At this time, Cytokinetics' Selling General Administrative is quite stable compared to the past year. Depreciation And Amortization is expected to rise to about 12.5 M this year, although the value of EBITDA is projected to rise to (460.1 M). Cytokinetics | Select Account or Indicator |
Cytokinetics Company Current Valuation Analysis
Cytokinetics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cytokinetics Current Valuation | 7.25 B |
Most of Cytokinetics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytokinetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cytokinetics Current Valuation Historical Pattern
Today, most investors in Cytokinetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cytokinetics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cytokinetics current valuation as a starting point in their analysis.
Cytokinetics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cytokinetics has a Current Valuation of 7.25 B. This is 49.53% lower than that of the Biotechnology sector and 56.06% higher than that of the Health Care industry. The current valuation for all United States stocks is 56.39% higher than that of the company.
Cytokinetics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cytokinetics's current stock value. Our valuation model uses many indicators to compare Cytokinetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cytokinetics competition to find correlations between indicators driving Cytokinetics's intrinsic value. More Info.Cytokinetics is rated fifth in return on equity category among related companies. It is rated fifth in return on asset category among related companies . At this time, Cytokinetics' Return On Equity is quite stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Cytokinetics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cytokinetics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cytokinetics' earnings, one of the primary drivers of an investment's value.Cytokinetics Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytokinetics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytokinetics could also be used in its relative valuation, which is a method of valuing Cytokinetics by comparing valuation metrics of similar companies.Cytokinetics is currently under evaluation in current valuation category among related companies.
Cytokinetics Fundamentals
| Return On Equity | -5.72 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (76.21) % | ||||
| Current Valuation | 7.25 B | ||||
| Shares Outstanding | 104.58 M | ||||
| Shares Owned By Insiders | 0.57 % | ||||
| Shares Owned By Institutions | 99.43 % | ||||
| Number Of Shares Shorted | 13.23 M | ||||
| Price To Earning | (37.76) X | ||||
| Price To Book | 31.90 X | ||||
| Price To Sales | 993.82 X | ||||
| Revenue | 7.53 M | ||||
| Gross Profit | (146.22 M) | ||||
| EBITDA | (484.31 M) | ||||
| Net Income | (526.24 M) | ||||
| Cash And Equivalents | 586.03 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 755.77 M | ||||
| Debt To Equity | 2.93 % | ||||
| Current Ratio | 9.01 X | ||||
| Book Value Per Share | (3.80) X | ||||
| Cash Flow From Operations | (414.33 M) | ||||
| Short Ratio | 4.22 X | ||||
| Earnings Per Share | (5.45) X | ||||
| Price To Earnings To Growth | (0.42) X | ||||
| Target Price | 95.06 | ||||
| Number Of Employees | 423 | ||||
| Beta | 0.68 | ||||
| Market Capitalization | 7.22 B | ||||
| Total Asset | 824.32 M | ||||
| Retained Earnings | (2.11 B) | ||||
| Working Capital | 525.37 M | ||||
| Current Asset | 113.11 M | ||||
| Current Liabilities | 31.65 M | ||||
| Net Asset | 824.32 M |
About Cytokinetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytokinetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 39.5 M | 41.5 M | |
| Total Revenue | 7.5 M | 7.2 M | |
| Cost Of Revenue | 11.9 M | 11.3 M | |
| Stock Based Compensation To Revenue | 9.57 | 10.05 | |
| Sales General And Administrative To Revenue | 23.06 | 24.21 | |
| Research And Ddevelopement To Revenue | 42.26 | 44.37 | |
| Capex To Revenue | (0.19) | (0.20) | |
| Revenue Per Share | 0.08 | 0.07 | |
| Ebit Per Revenue | (65.90) | (62.60) |
Pair Trading with Cytokinetics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.Moving against Cytokinetics Stock
| 0.78 | MRSN | Mersana Therapeutics Downward Rally | PairCorr |
| 0.71 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.59 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.56 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.54 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cytokinetics Piotroski F Score and Cytokinetics Altman Z Score analysis. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Cytokinetics Stock analysis
When running Cytokinetics' price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.078 | Quarterly Revenue Growth (0.15) | Return On Assets (0.34) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.